ArticleCardiovascular diagnosis and therapy2026
Long-term high-sensitivity C-reactive protein trajectories and risk of major adverse cardiovascular events in statin-treated patients: a retrospective cohort.
Article in Cardiovascular diagnosis and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-sensitivity C-reactive protein (hs-CRP) is a key inflammatory marker in atherosclerosis; however, the association between its long-term patterns and cardiovascular prognosis under statin therapy remains incompletely understood. This study characterized hs-CRP trajectories and their prognostic value for MACE in statin users, aiming to refine risk assessment and tailored therapy. Methods: We conducted a retrospective cohort study at the Center for Coronary Artery Disease, Beijing Anzhen Hospital, Capital Medical University (Beijing, China), using data from patients who received statin therapy for at least 12 months between January 2023 and December 2024. Eligible participants had three or more hs-CRP measurements and were free from major adverse cardiovascular events (MACEs) six months before enrollment. Latent class growth modeling was applied to categorize hs-CRP trajectories. The primary composite outcome included cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or rehospitalization for unstable angina. Event-free survival was compared across trajectory groups using Kaplan-Meier curves with log-rank testing. Multivariable Cox proportional hazards regression evaluated the association between hs-CRP trajectories and MACE, with adjustments for age, sex, hypertension, diabetes, baseline lipids, and statin intensity. Results: This study included 210 patients with a median follow-up of 11.9 months. Latent class growth modeling identified three distinct hs-CRP trajectories: persistently low (45.2%, <2 mg/L), moderately fluctuating (40.0%, 2-5 mg/L), and persistently high (14.8%, ≥5 mg/L). Over follow-up, 38 patients (18.1%) experienced a MACE. Kaplan-Meier analysis revealed significantly higher cumulative MACE incidence in persistently high compared to persistently low (38.7% Conclusions: Statin-treated patients with rising hs-CRP levels face elevated MACE risk. Longitudinal patterns show prognostic promise but need validation in future trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.